Search results
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Reuters via Yahoo Singapore Finance· 3 months agoIndian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early...
Biocon may list biosimilars business by 2025 first half - CEO
Reuters via Yahoo Singapore Finance· 11 months agoIndian biopharmaceutical company Biocon Ltd is planning to list its biosimilars business, a...
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
Zacks via Yahoo News· 2 years agoViatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its...
Viatris (VTRS) Down 1.5% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Singapore Finance· 2 years agoA month has gone by since the last earnings report for Viatris (VTRS). Shares have lost about 1.5%...
India's Biocon seeks partner to test generic Wegovy, Ozempic in China
Reuters via Yahoo News Singapore· 3 weeks agoIndia's Biocon is searching for a partner in China to test generic versions of Novo Nordisk's hot-selling diabetes drug Ozempic and weight loss treatment Wegovy, a senior executive told Reuters ...
India's Biocon posts Q4 profit fall as higher raw material costs bite
Reuters via Yahoo News Singapore· 2 months agoIndian biopharmaceutical company Biocon reported a decline in its fourth-quarter profit on Thursday, as soaring raw material costs overshadowed growth in its biosimilar business in key United ...
India's Biocon raises $129 million from Kotak to fund biosimilars deal
Reuters via Yahoo News Singapore· 1 year agoBiocon Biologics completed the $3.34-billion acquisition of U.S.-based Viatris's biosimilars business in late November. At the time, the company said it paid $2 billion in cash to Viatris and ...
India's Biocon Q1 profit falls on higher R&D spending
Reuters via Yahoo News Singapore· 11 months agoHYDERABAD (Reuters) - India's Biocon on Thursday posted a 29.8% fall in June-quarter profit, hurt by increased spending in research and development (R&D). Consolidated net profit attributable ...
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million
Reuters via Yahoo News Singapore· 4 months agoBENGALURU (Reuters) -Biopharmaceutical company Biocon's unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences in a deal worth 12.42 billion rupees ( ...
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns
Reuters via Yahoo Singapore Finance· 5 months agoIndian biopharmaceutical company Biocon Ltd swung to a third-quarter profit on Thursday, boosted by its biosimilars business and the sale of some of its non-core units, and said Chief Financial ...
